Drug Trial Radar · NCT04371627
Viaskin® Peanut (DBV712) Expanded Access Protocol
Last checked: Nov 19, 2026Latest source record: May 28, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
No longer available
Enrollment
Not stated
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- DBV TechnologiesIndustry
- Sponsor type
- Industry
- First posted
- May 1, 2020
Design
- Study type
- Expanded access
- Who can join
- All sexes, from 4 years, up to 12 years
Summary
As written by the sponsor on the registry.
This is an open label expanded access program for male and female patients ≥ 4 years old.
Conditions
- Peanut Allergy
Interventions
Viaskin PeanutDrug
Daily epicutaneous delivery
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.